Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

Hagop Kantarjian, Yasuhiro Oki, Guillermo Garcia-Manero, Xuelin Huang, Susan O'Brien, Jorge Cortes, Stefan Faderl, Carlos Bueso-Ramos, Farhad Ravandi, Zeev Estrov, Alessandra Ferrajoli, William Wierda, Jianqin Shan, Jan Davis, Francis Giles, Hussain I. Saba, Jean-Pierre J. Issa

Blood (2006) 109 (1): 52–57.

https://doi.org/10.1182/blood-2006-05-021162

Published: 2006

Journal Articles

Decitabine Low-Dose Schedule (100 mg/m 2 /Course) in Myelodysplastic Syndrome (MDS). Comparison of 3 Different Dose Schedules.

Hagop Kantarjian, MD, Susan O’Brien, MD, Francis Giles, MD, Farhad Ravandi-Kashani, MD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Jan Davis, BS, ADN, Jean-Pierre Issa, MD

Blood (2005) 106 (11): 2522.

https://doi.org/10.1182/blood.V106.11.2522.2522

Published: 2005

Journal Articles

Final Results of a Phase I Study of the Histone Deacetylase Inhibitor Vorinostat (Suberoyanilide Hydroxamic Acid, SAHA), in Patients with Leukemia and Myelodysplastic Syndrome.

Guillermo Garcia-Manero, MD, Hui Yang, MD, PhD, Blanca Sanchez-Gonzalez, MD, Srdan Verstovsek, MD, Alessandra Ferrajoli, MD, Michael Keating, MD, Michael Andreeff, MD, Susan O’Brien, MD, Jorge Cortes, MD, William Wierda, MD, PhD, Stefan Faderl, MD, Charles Koller, MD, Jan Davis, RN, Gail Morris, RN, Jean-Pierre Issa, MD, Stanley R. Frankel, MD, Victoria Richon, PhD, Bernard Fine, PhD, Hagop Kantarjian, MD

Blood (2005) 106 (11): 2801.

https://doi.org/10.1182/blood.V106.11.2801.2801

Published: 2005

Journal Articles

Decitabine Low-Dose Schedule (100 mg/m 2 /course) in Myelodysplastic Syndrome (MDS). Comparison of 3 Different Dose Schedules.

Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Susan O’Brien, MD, Francis Giles, MD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Jan Davis, Elihu Estey, MD, Jean-Pierre Issa.

Blood (2004) 104 (11): 1437.

https://doi.org/10.1182/blood.V104.11.1437.1437

Published: 2004

Journal Articles

Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia

Hagop Kantarjian, Varsha Gandhi, Jorge Cortes, Srdan Verstovsek, Min Du, Guillermo Garcia-Manero, Francis Giles, Stefan Faderl, Susan O'Brien, Sima Jeha, Jan Davis, Zeev Shaked, Adam Craig, Michael Keating, William Plunkett, Emil J Freireich

Blood (2003) 102 (7): 2379–2386.

https://doi.org/10.1182/blood-2003-03-0925

Published: 2003

NARROW

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

Decitabine Low-Dose Schedule (100 mg/m 2 /Course) in Myelodysplastic Syndrome (MDS). Comparison of 3 Different Dose Schedules.

Final Results of a Phase I Study of the Histone Deacetylase Inhibitor Vorinostat (Suberoyanilide Hydroxamic Acid, SAHA), in Patients with Leukemia and Myelodysplastic Syndrome.

Decitabine Low-Dose Schedule (100 mg/m 2 /course) in Myelodysplastic Syndrome (MDS). Comparison of 3 Different Dose Schedules.

Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia

Email alerts

ASH Publications

American Society of Hematology

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

Decitabine Low-Dose Schedule (100 mg/m 2 /Course) in Myelodysplastic Syndrome (MDS). Comparison of 3 Different Dose Schedules.

Final Results of a Phase I Study of the Histone Deacetylase Inhibitor Vorinostat (Suberoyanilide Hydroxamic Acid, SAHA), in Patients with Leukemia and Myelodysplastic Syndrome.

Decitabine Low-Dose Schedule (100 mg/m 2 /course) in Myelodysplastic Syndrome (MDS). Comparison of 3 Different Dose Schedules.

Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only